Biologics in oral medicine: Principles of use and practical considerations

Oral Diseases

Volumn 18, Issue 6, 2012, Pages 525-536

  O'Neill, I D ^a   Scully, C ^b  

^a Centre d'Affaires Poincare   (France)

^b WHO Collaborating Centre for Oral Health General Health and University College London   (United Kingdom)

Author keywords

Adalimumab; Adverse effects; Biologics; Etanercept; Infliximab; Monitoring; Rituximab; TNF alpha antagonists

Indexed keywords

ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; NATALIZUMAB; RITUXIMAB; USTEKINUMAB;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BEHCET DISEASE; BIOLOGICAL THERAPY; BLOOD CELL COUNT; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CELLULITIS; CONCEPTION; CROHN DISEASE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HEART FAILURE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LACTATION; LIVER FUNCTION TEST; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUTH CANCER; NEUROLOGIC DISEASE; NEUTROPENIA; OROFACIAL GRANULOMATOSIS; OSTEOMYELITIS; PARAINFLUENZA VIRUS INFECTION; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STOMATOLOGY; SYSTEMIC DISEASE; TREATMENT RESPONSE; URTICARIA; VIRUS LOAD; VIRUS PNEUMONIA;

BIOLOGICAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKINS; LYMPHOCYTES; ORAL MEDICINE; PHARMACEUTICAL PREPARATIONS, DENTAL; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864861494     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01919.x     Document Type: Review

References (131)

1. Ahmed AR, Spigelman Z, Cavacini LA, Poster MR (2006). Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772-1779.
2. Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K (2011). Malignancies after rituximab treatment: just coincidence or more? J BUON 16: 112-115.
3. Armstrong D, Wright S, McVeigh C, Finch M (2006). Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis? Clin Rheumatol 25: 583-584.
4. Asarch A, Gottlieb AB, Lee J et al (2009). Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor alpha antagonists. J Am Acad Dermatol 61: 104-111.
5. van Assen S, Agmon-Levin N, Elkayam O et al (2011). ULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70: 414-422.
6. Barouta G, Karapetsa M, Kostopoulou E, Alexiou I, Koukoulis G, Sakkas LI (2010). Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab. J Clin Rheumatol 16: 330-331.
7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285.
8. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M (2009). ullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 219: 357-358.
9. Boussemart L, Jacobelli S, Batteux F et al (2010). Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 221: 201-205.
10. Brennan A, Bansback N, Nixon R et al (2007). Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46: 1345-1354.
11. den Broeder AA, Creemers MC, Fransen J et al (2007). Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34: 689-695.
12. Buch MH, Smolen JS, Betteridge N et al (2011). Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909-920.
13. Bukhari M, Abernethy R, Deighton C et al (2011). BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50: 2311-2313.
14. Calabrese LH, Zein N, Vassilopoulos D (2004). Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63: ii18-ii24.
15. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB (2009). A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36: 635-641.
16. Caspersen S, Elkjaer M, Riis L et al (2008). Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6: 1212-1217.
17. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008). The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67: 710-712.
18. Cheifetz A, Smedley M, Martin S et al (2003). The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98: 1315-1324.
19. Cheng A, Mann C (2006). Oral erosive lichen planus treated with efalizumab. Arch Dermatol 142: 680-682.
20. Chong BF, Wong HK (2007). Immunobiologics in the treatment of psoriasis. Clin Immunol 123: 129-138.
21. Ciantar M, Adlam DM (2007). Treatment with infliximab: implications in oral surgery? A case report. Br J Oral Maxillofac Surg 45: 507-510.
22. Clifford DB, Ances B, Costello C et al (2011). Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156-1164.
23. Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008). Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59: 996-1001.
24. Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S (2011). Rituximab for the treatment of corticosteroid - refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med 40: 616-620.
25. Cunha BA, D'Elia AA, Pawar N, Schoch P (2010). Viridans streptococcal (Streptococcus intermedius) mitral valve subacute bacterial endocarditis (SBE) in a patient with mitral valve prolapse after a dental procedure: the importance of antibiotic prophylaxis. Heart Lung 39: 64-72.
26. Daïen CI, Cohen JD, Makinson A et al (2010). Whipple's endocarditis as a complication of tumour necrosis factor-alpha antagonist treatment in a man with ankylosing spondylitis. Rheumatology (Oxford) 49: 1600-1602.
27. Daulat S, Detweiler JG, Pandya AG (2009). Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 23: 483-484.
28. Deighton C, Hyrich K, Ding T et al (2010). BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 49: 1197-1199.
29. Deneau M, Wallentine J, Guthery S et al (2010). Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. Pediatrics 126: e977-e981.
30. D'Haens GR, Panaccione R, Higgins PD et al (2011). The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199-212.
31. Ding T, Ledingham J, Luqmani R et al (2010). BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 49: 2217-2219.
32. Dixon W, Felson DT (2011). Is anti-TNF therapy safer than previously thought? JAMA 306: 2380-2381.
33. Dixon WG, Hyrich KL, Watson KD et al (2010). Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522-528.
34. Doherty SD, Van Voorhees A, Lebwohl MG et al (2008). National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59: 209-217.
35. Domm S, Cinatl J, Mrowietz U (2008). The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 159: 1217-1228.
36. Ducharme J, Pelletier C, Zacharias R (2010). The safety of infliximab infusions in the community setting. Can J Gastroenterol 24: 307-311.
37. Dunleavy K, Tay K, Wilson WH (2010). Rituximab-associated neutropenia. Semin Hematol 47: 180-186.
38. Edwards BJ, Hellstein JW, Jacobsen PL et al (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139: 1674-1677.
39. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA (2010). Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford) 49: 1505-1512.
40. El-Hallak M, Binstadt BA, Leichtner AM et al (2007). Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150: 376-382.
41. Elliott E, Campbell H, Escudier M et al (2011). Experience with anti-TNF-α therapy for orofacial granulomatosis. J Oral Pathol Med 40: 14-19.
42. Emer JJ (2009). Is there a potential role for anti-tumor necrosis factor therapy in patients with human immunodeficiency virus? J Clin Aesthet Dermatol 2: 29-35.
43. Ernst D, Bange FC, Rana A et al (2010). [Reactivation of tuberculosis with Mycobacterium bovis infection of the oral mucosa during immunosuppression]. Dtsch Med Wochenschr 135: 1179-1181.
44. Favero M, Raffeiner B, Cecchin D, Schiavon F (2009a). Septic arthritis caused by Rothia dentocariosa in a patient with rheumatoid arthritis receiving etanercept therapy. J Rheumatol 36: 2846-2847.
45. Favero M, Schiavon F, Riato L, Carraro V, Punzi L (2009b). Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. Autoimmun Rev 8: 59-61.
46. Fleischmann RM (2009). Progressive multifocal leukoencephalopathy following rituximab treatment in patient with rheumatoid arthritis. Arthritis Rheum 60: 3225-3228.
47. Furst DE, Keystone EC, Braun J et al (2011). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 70(Suppl. 1): i2-i36.
48. Galloway JB, Hyrich KL, Mercer LK et al (2011). Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50: 124-131.
49. Gaya DR, Aitken S, Fennell J, Satsangi J, Shand AG (2006). Anti-TNF-α therapy for orofacial granulomatosis: proceed with caution. Gut 55: 1524-1525.
50. Giles JT, Bartlett SJ, Gelber AC et al (2006). Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55: 333-337.
51. Gottenberg JE, Ravaud P, Bardin T et al (2010). Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62: 2625-2632.
52. Graves JE, Nunley K, Heffernan MP (2007). Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol 56: e55-e79.
53. Grijalva CG, Chen L, Delzell E et al (2011). Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306: 2331-2339.
54. Grim SA, Pham T, Thielke J et al (2007). Infectious complications associated with the use of rituximab for ABO incompatible and positive cross-match renal transplant recipients. Clin Transplant 21: 628-632.
55. Hashkes PJ, Uziel Y, Laxer RM (2010). The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 6: 561-571.
56. Hastings R, Ding T, Butt S et al (2010). Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 62: 764-769.
57. Hatemi G, Silman A, Bang D et al (2008). EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67: 1656-1662.
58. Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE (2007). A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol 6: 310-314.
59. Hertl M, Zillikens D, Borradori L et al (2008). Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6: 366-373.
60. Hertl M, Bernard P, Borradori L (2011). Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice? Arch Dermatol 147: 855-856.
61. Hoffmann C, Schmid H, Müller M et al (2011). Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118: 3499-3503.
62. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC (2011). Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 8: 43-54.
63. Kahwaji J, Sinha A, Toyoda M et al (2011). Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 6: 2894-2900.
64. Kain T, MacGregor D, Buchanan RR, de Jager JP, Schachna L (2008). Erythema multiforme with tumour necrosis factor inhibitors: a class effect? Ann Rheum Dis 67: 899-900.
65. Kaneko U, Kishi T, Kikuchi M et al (2010). [Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy]. Nihon Rinsho Meneki Gakkai Kaishi 33: 157-161.
66. Kelesidis T, Salhotra A, Fleisher J, Uslan DZ (2010). Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 60: 386-396.
67. Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011). Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15: e2-e16.
68. Kerbleski JF, Gottlieb AB (2009). Dermatological complications and safety of anti-TNF treatments. Gut 58: 1033-1039.
69. Keyser FD (2011). Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev 7: 77-87.
70. Kolho KL, Heiskanen K, Verkasalo M, Pitkäranta A (2011). Orofacial granulomatosis in children - A challenge for diagnosis and treatment. Int J Pediatr Otorhinolaryngol 75: 864-867.
71. Kolokotronis A, Avramidou E, Zaraboukas T, Mandraveli K, Alexiou S, Antoniades D (2006). Oral tuberculosis associated with a treatment with anti-rheumatic drugs. J Oral Pathol Med 35: 123-125.
72. Korman BD, Tyler KL, Korman NJ (2009). Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 145: 937-942.
73. Kumar D, Bouldin TW, Berger RG (2010). A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62: 3191-3195.
74. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M et al (2011). Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 147: 843-849.
75. Leão JC, Duarte A, Gueiros LA et al (2005). Severe oral epithelial dysplasia in a patient receiving adalimumab therapy. J Oral Pathol Med 34: 447-448.
76. Lebwohl M, Bagel J, Gelfand JM et al (2008). From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58: 94-105.
77. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA (2008). Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 159: 527-536.
78. Lequerré T, Vittecoq O, Klemmer N et al (2006). Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33: 1307-1314.
79. Lourari S, Herve C, Doffoel-Hantz V et al (2011). Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 25: 1238-1240.
80. Mabrouk D, Ahmed AR (2011). Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. Pediatr Dermatol 28: 485-493.
81. Mahadevan U, Cucchiara S, Hyams JS et al (2011). The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 106: 214-223.
82. Mann DL, McMurray JJ, Packer M et al (2004). Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602.
83. Mayer Y, Balbir-Gurman A, Machtei E (2009). Anti-tumour necrosis factor -alpha therapy and periodontal parameters in patients with rheumatoid arthritis. J Periodontol 80: 1414-1420.
84. Menon K, Van Voorhees AS, Bebo BF Jr. et al (2010). Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 62: 291-299.
85. Menter A, Gottlieb A, Feldman SR et al (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58: 826-850.
86. Mocciaro F, Orlando A, Renna S, Rizzuto MR, Cottone M (2011). Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease. J Crohns Colitis 5: 173-174.
87. Molloy ES (2011). PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med 78(Suppl. 2): S28-S32.
88. Munson MA, Banerjee A, Watson TF, Wade WG (2004). Molecular analysis of the microflora associated with dental caries. J Clin Microbiol 42: 3023-3029.
89. Narayana N, Gifford R, Giannini P, Casey J (2009). Oral histoplasmosis: an unusual presentation. Head Neck 31: 274-277.
90. Ng WF, Bowman SJ, Griffiths B, UKPSSR study group (2011). United Kingdom Primary Sjogren's Syndrome Registry - a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford) 50: 32-39.
91. Ollendorf DA, Klingman D, Hazard E, Ray S (2009). Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 31: 825-835.
92. O'Neill ID (2008). Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 37: 575-581.
93. O'Neill I (2010). Guidance on the use of biological agents in the treatment of oral mucosal disease. Br J Dermatol 162: 1410-1411.
94. Ortiz P, Bissada NF, Palomo L et al (2009). Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumour necrosis factor inhibitors. J Periodontol 80: 535-540.
95. Paltiel M, Gober LM, Deng A et al (2008). Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 144: 1190-1194.
96. Perlmutter A, Mittal A, Menter A (2008). Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 160: 8-15.
97. Pers JO, Saraux A, Pierre R, Youinou P (2008). Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol 79: 1645-1651.
98. Rahman N, Healy C, Flint SR, Stassen LF (2010). Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. J Clin Rheumatol 16: 197-199.
99. Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N (2009). Cancer of the cheek in a patient under etanercept]. Rev Stomatol Chir Maxillofac 110: 306-308.
100. Ryan C, Leonardi CL, Krueger JG et al (2011). Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864-871.
101. Saag KG, Teng GG, Patkar NM et al (2008). American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59: 762-784.
102. Salama M, Lawrance IC (2009). Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol 15: 4449-4452.
103. Sanchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, Ruiz-Villaverde R (2006). Urticaria and angioedema in a patient with Behcet's disease treated with adalimumab. Clin Exp Rheumatol 24(5 Suppl. 42): S128.
104. Saulsbury FT, Mann JA (2003). Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 49: 599-600.
105. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ (2011). Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. doi: 10.3111/13696998.2011.644645. Dec 8. [Epub ahead of print]
106. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M (2007). Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156: 352-356.
107. Seeborg FO, Rihal PS, Czelusta A, Sanchez R, Hanson IC (2009). Lichen planus associated with omalizumab administration in an adult with allergic asthma. Ann Allergy Asthma Immunol 102: 349-351.
108. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S (2010). Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 31: 20-34.
109. Shenoi S, Wallace CA (2010). Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 12: 367-377.
110. Shirota Y, Illei GG, Nikolov NP (2008). Biologic treatments for systemic rheumatic diseases. Oral Dis 14: 206-216.
111. Singh JA, Wells GA, Christensen R et al (2011). Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2: CD008794.
112. Slimani S, Lukas C, Combe B, Morel J (2011). Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 78: 484-487.
113. Smith CH, Anstey AV, Barker JN et al (2009). British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161: 987-1019.
114. Söderlin M, Blomkvist C, Dahl P, Forsberg P, Fohlman J (2005). [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports]. Lakartidningen 102: 3794-3796, 3799-3800.
115. Sparano JA, Lee JY, Kaplan LD et al (2010). Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115: 3008-3016.
116. Stasi R (2010). Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 47: 170-179.
117. Sukhatme SV, Gottlieb AB (2009). Pediatric psoriasis: updates in biologic therapies. Dermatol Ther 22: 34-39.
118. Sussman JI, Baron EJ, Tenenbaum MJ et al (1986). Viridans streptococcal endocarditis: clinical, microbiological, and echocardiographic correlations. J Infect Dis 154: 597-603.
119. Tesfa D, Ajeganova S, Hägglund H et al (2011). Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63: 2209-2214.
120. Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN (2009). Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 23: 348-352.
121. Thornhill J, Watson KD, Lord PA, Symmons DP, Hyrich KL (2009). Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR Biologics Register. Rheumatology 47(Suppl. 2): ii15.
122. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008). Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83: 181-194.
123. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J (2009). Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2: 6609.
124. Van Assche G, Lewis JD, Lichtenstein GR et al (2011). The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 106: 1594-1602.
125. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium, BSR Biologics Register (2011). Concise report: anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70: 823-826.
126. van Vollenhoven RF, Emery P, Bingham CO 3rd et al (2010). Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37: 558-567.
127. Wolfe F, Michaud K (2011). The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 50: 16-24.
128. Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S (2011). Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm 17: 313-320.
129. Zhang J, Zhou G, Du GF, Xu XY, Zhou HM (2011). Biologics, an alternative therapeutic approach for oral lichen planus. J Oral Pathol Med 40: 521-524.
130. Zone JJ (2011). Taking responsibility for complex medical dermatology patient management: comment on "rituximab for patients with refractory mucous membrane pemphigoid". Arch Dermatol 147: 850.
131. Zribi H, Crickx B, Descamps V (2007). Prevention of recurrent aphthous stomatitis by efalizumab (Raptiva®). J Eur Acad Dermatol Venereol 21: 1286-1287.